News & Insights


EU’s New Falsified Medicines Directive – What You Need to Know About Safety Features

The European Union’s Falsified Medicines Directive (FMD) has been in force since February 9, 2019, obliging pharmaceutical manufacturers to equip their products with so-called “safety features,” namely a unique identifier as well as an anti-tampering device. This webinar will:

  • Include a step-by-step review of the FMD’s new obligations for pharmaceutical manufacturers.
  • Provide guidance on safety feature verification by wholesalers, pharmacies, and hospitals and introduce the new repositories system.
  • Contain discussion of some hot topics regarding the implementation of the safety features, including the responsibilities in case of parallel imports and the provisions of “FMD Hospital Pharmacy Services.”

Tuesday, March 26, 2019
12:00 P.M. – 1:00 P.M. ET

CLE credit will be applied for in CA, GA, IL, NY, TX and, if needed, NC and VA. Attendees will receive a Uniform Certificate of Attendance via email approximately 30 days after the program to seek CLE credit in other jurisdictions. New York lawyers: This program is considered transitional and non-transitional in content. The interactive webinar format is synchronous and approved for all lawyers. King & Spalding LLP / 1180 Peachtree Street, Atlanta, GA 30309 | CA Provider # 10947.

General information on our practice is available in our electronic publications Serving the Life Sciences Industry and Serving the Healthcare Industry. If you would like to be included on our regular pharmaceutical manufacturers, medical device manufacturers or healthcare provider mailing lists to receive notices of other events and written updates, you can be added by submitting your full contact information to and specifying the list you wish to join.

If you have questions concerning this roundtable webinar, email

Event Details

Date: March 26, 2019

Time: 12:00 pm (ET)

Attend This Event

Please register soon. You do not have to be a client to attend, and there is no charge.